Search results

Not sure, was thinking there might be a higher risk of selection bias and not getting a representative sample of the ME/CFS population.

The replication with existing databases does not seem to go very well: there's likely too much uncertainty about the case definition used. So I suspect that another project with the same approach as DecodeME might be needed to confirm the results. It will need to be in an area were ME/CFS is...

Apologies if this is a stupid question but how do you know which SNPs are measured and which ones are imputed? Do they mention this somewhere in the text or is it somewhere in the data?

EDIT: these probably reflect artefacts that were excluded in the main analysis? I'm looking at the DecodeME summary data, namely the file: gwas_1.regenie.gz taken from here: https://osf.io/rgqs3/files/osfstorage When I arrange by lowest p-value however, I get 8320 rows with a p-value lower...

Yes strange. Perhaps the overall frequency was taken from another database and does not reflect the data in DecodeME?

Here's an overview of the replication cohorts' sample sizes (taken from the supplementary material): Replication Cohort Cases Controls R1 Lifelines 3,440 17,080 R1 UK Biobank 10,327 195,103 R2 Estonian Biobank 1,926 195,103 R2 FinnGen 283 463,029 R2 Michigan Genomics Initiative...

I noticed that the HLA-region also got a significant finding (HLA-DQA1*05:01 at p = 1.4 x 10-10 but that it somehow reported separately form the other 8 hits. It seems to be a different SNP than what the Norwegians found but perhaps this is due to HLA being difficult to sequence?

The failed replications are disappointing but I suspect that next too broad case definitions for ME/CFS in the other databases, the sample size might also have been too small. In the supplementary material it says that the Lifelines cohort only had 3,440 cases and 17,080 controls (compared to...

Made a brief summary of the results here (EDIT: added full text and Bluesky link) Link to Bluesky: 1) The DecodeME study compared DNA of ca. 15,000 ME/CFS patients and 250,000 controls and found significant differences in 8 regions of our genome. The Manhattan plot below shows the genes and...

I think this is normal for GWAS, they provide clues or pointers to what's going wrong rather than the gene being the culprit behind ME/CFS.

To get a feel of the effect size, I've made an overview of the prevalence of these SNPs in patients versus controls. I couldn't find this in the paper or supplementary material so I've tried to calculate them using R (trying out different guesses until the combined prevalence and odds ratio...

No email yet but seeing some articles being published: Key genetic differences found in people with chronic fatigue syndrome | New Scientist

Thanks for posting Dolphin. The post shows Jaime Seltzer writing:

This is mentioned here in this documentary (38:20): Scheibenbogen later commented on this: https://www.healthrising.org/blog/2021/09/16/autoimmune-options-chronic-fatigue-syndrome-scheibenbogen/

Yes I think so. Perhaps others can double-check.

I heard people suggest that the dosage might be different (and that the Norwegian trial couldn't provide the dosage because of lack of funding). Not sure if this is true. Here's what I could find online: Fluge et al. 2011 (pilot RCT, n=30) Rituximab 500 mg/m2 given twice two weeks apart, with...

There's some more info about this trial in the presentation by Dr Sato during the Berlin conference: Here are some slides:

I also wonder how this relates to the study by @chillier which found no difference in oxygen consumption rate when ME/CFS serum was added to myoblasts. Do these studies contradict each other?

Yes it looks interesting but it seems that this is not for LC in general but for a relatively rare complication called 'Multisystem inflammatory syndrome in children (MIS-C)' This page says: https://www.mayoclinic.org/diseases-conditions/mis-c-in-kids-covid-19/symptoms-causes/syc-20502550

The first sentence is: This also looks strange, perhaps written by an AI? The first author Martin Toby published a case series on chronic symptoms following EBV in 1982 in the Lancet. https://pubmed.ncbi.nlm.nih.gov/6119490/